Oncotarget

Research Papers:

MicroRNA424/E2F6 feedback loop modulates cell invasion migration and EMT in endometrial carcinoma

PDF  |  Full Text  |  How to cite

Oncotarget. 2017; 8:114281-114291. https://doi.org/10.18632/oncotarget.23218

Metrics: PDF 1945 views  |  Full Text 3051 views

Zheng Lu1, Zhou Nian1, Zhang Jingjing1, Luo Tao1 and Li Quan1

1Department of Gynaecology, The First Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou 563000, P.R. China

Correspondence to:

Li Quan, email: [email protected]

Keywords: miR-424; E2F6; endometrial carcinoma

Received: August 23, 2017     Accepted: October 28, 2017     Published: December 13, 2017

ABSTRACT

Our previous study explored the roles of microRNA-424 (miR-424) in the development of endometrial carcinoma (EC) and analyzed the miR-424/E2F7 axis in EC cell growth. In this study, we investigated the status of miR-424 in human endometrial cancer tissues, which were collected from a cohort of Zunyi patients. We found that the expression level of miR-424 was associated with clinical tumor stage, cell differentiation, lymph node metastasis and cell migration ability. Cell function experiments demonstrated that miR-424 overexpression suppressed the invasion and migration abilities of endometrial carcinoma cells in vitro. Bioinformatic predictions and dual-luciferase reporter assays suggested E2F6 as a possible target of miR-424. RT-PCR and western blot assays demonstrated that miR-424 transfection reduced the expression level of E2F6, while inhibiting miR-424 with ASO-miR-424 (antisense oligonucleotides of miR-424) increased the expression level of E2F6. Cell function experiments indicated that E2F6 transfection rescued the EC cell phenotype induced by miR-424. In addition, we also found that E2F6 negatively regulated miR-424 expression in EC cells. In summary, our results demonstrated that the miR-424/E2F6 feedback loop modulates cell invasion, migration and EMT in EC and that the miR-424/E2Fs regulation network may serve as a new and potentially important therapeutic target in EC.